An observational study in Atrial Fibrillation, sponsored by Policlinico Casilino ASL RMB. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.
Sponsored by Policlinico Casilino ASL RMB · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia with prevalence and incidence continuously increasing worldwide. Current guidelines propose an etiological, symptom-based classification of the arrhythmia and mainly focused on its duration with consequent rhythm or rate-control strategies. Moreover, risk scores for atherothrombotic systemic or hemorrhagic events related to atrial fibrillation are principally based on patients cardiovascular history and risk factors.
This approach do not consider relevant pathophysiological aspects that may play a pivotal role in triggering or perpetuating the arrhythmia, especially at its first occurrence. At this point, a crucial step would be deeply investigating AF clinical and pathophysiological features to guide a tailored diagnostical and therapeutic approach. Indeed, early recognition and proper characterization of triggers, substrates, autonomic system imbalance and modulating factors (drugs, electrolytes, etc) are of the utmost importance for AF care and management.
Therefore, this large scale prospective observational study aims to evaluate clinical and pathophysiological features of patients with symptomatic and asymptomatic atrial fibrillation in different scenarios to understand possible distinctive characteristics warranting a personalized approach to the arrhythmia.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
This study's planned enrollment of 5,000 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Browse Atrial Fibrillation studies →Policlinico Casilino ASL RMB is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
In this prospective observational study we consider to enroll patients with diagnosis of Atrial Fibrillation (new onset, paroxysmal, persistent, long-persistent and permanent) admitted to our Hospital in the Emergency Room and/or Cardiology Department/Ambulatory Care Center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rate of Atrial Fibrillation recurrences
frequency distribution
Time frame: 5 years
Number of participants with Major Adverse Cardiac Events (MACE)
frequency distribution
Time frame: 5 years
Rate of thromboembolic events
frequency distribution
Time frame: 5 years
Rate of bleeding events
frequency distribution of minor, major and fatal bleedings
Time frame: 5 years
Rate of participants socio-demographic characteristics
Frequency distribution: age, gender, race, occupation, life-style, diet, physical activity, alcohol consumption
Time frame: baseline and 5 years
Rate of participants with comorbidities
Frequency distribution: hypertension, heart failure, diabetes mellitus, kidney failure, dyslipidemia, lung diseases, thyroid disorders, gastrointestinal and liver disorders, hematological diseases, neoplasms, autoimmune disorders
Time frame: baseline and 5 years
Rate of participants with Heart diseases
frequency distribution: vascular diseases, valvular problems, cardiomyopathies, arrhythmias, family/genetic history of cardiovascular disease
Time frame: baseline and 5 years
Rate of patients with Atrial Fibrillation secondary to triggers and/or autonomic system imbalance and/or modifiable factors
Frequency distribution of patients in which atrial fibrillation was clearly related to adrenergic tone imbalance and/or vagal tone imbalance and/or secondary to modifiable factors
Time frame: baseline and 5 years
Describe imaging parameters (echocardiogram and cardiac magnetic resonance)
Left ventricle, right ventricle, right and left atrium and valves: morphologies, volumes, dimensions and function
Time frame: baseline and 5 years
Concentration of laboratory biomarkers
Complete Blood cell count with differential; Interleukin-1, Interleukin-6, High sensitivity C Reactive protein
Time frame: baseline and 5 years
No study locations are listed for this record.
Plan to share: No
Start is estimated for Apr 2020; primary completion for Apr 2022, 24 months later.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 24 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Policlinico Casilino ASL RMB